Janney Montgomery Scott analyst Robert Stevenson downgrades Gladstone Commercial (NASDAQ:GOOD) from Buy to Neutral.
JP Morgan Upgrades Allogene Therapeutics to Overweight, Lowers Price Target to $11
JP Morgan analyst Brian Cheng upgrades Allogene Therapeutics (NASDAQ:ALLO) from Neutral to Overweight and lowers the price target from $20 to $11.